Dr. Wang obtained his BA from Harvard University and his MD, PhD degrees from University of Texas Southwestern and University of Paris in 2011. He did internal medicine housestaff training at Yale, joining the ABIM Short Track Pathway into Rheumatology fellowship. As a part of his MD/PhD training in the laboratories of Drs. Edward Wakeland and Chandra Mohan, he identified a key role for the CXCR4/SDF-1 axis in end-organ targeting, an important insight in the pathogenesis of SLE. He has also worked to coordinate international translational studies for targeted CXCR4 therapy. Dr. Wang published 10 papers during his training with a strong focus on autoimmune disorders.
Dr. Wang joined the lab of Dr. Ruslan Medzhitov in July 2014, which has unparalleled expertise in the biology of inflammation. His project addresses how the immune system integrates multiple environmental signals in an effort to identify novel negative regulators of inflammation that may have therapeutic potential in the treatment of diseases of pathologic inflammation like SLE. He is currently studying metabolic control of inflammation.
Education & Training
|MD/PhD||University of Paris V, Immunobiology (2011)|
|MD/PhD||University of Texas Southwestern Medical School, Immunobiology (2011)|
|AB||Harvard University, Biochemistry (2004)|
|ABIM Research Pathway Resident||Yale University School of Medicine/Yale New Haven Hospital|
|Postdoctoral Fellow||University of Texas Southwestern Medical School|